Patent Thickets Decoded: How to Find the Real Expiration Date for Blockbuster Drug Patents
The expiration date on a blockbuster drug’s primary patent is almost never the date generic competition arrives. Between that printed […]
Data Beats Capital: Why the Real Challenger in Pharma IP Is the One Who Knows More
Every few years, a mid-size generic manufacturer files a Paragraph IV certification against a blockbuster drug, gets sued by a
Data Beats Capital: Why the Real Challenger in Pharma IP Is the One Who Knows More Read Post »
Sentiment Analysis in Patent Litigation: How to Predict Pharmaceutical Case Outcomes
Pharmaceutical patent litigation produces more text per dollar at stake than almost any other legal domain. A single Hatch-Waxman case
Sentiment Analysis in Patent Litigation: How to Predict Pharmaceutical Case Outcomes Read Post »
First-to-Market vs. Most-Efficient-to-Market: Why Speed Alone Loses the Generic Drug Race
The conventional wisdom in generic pharmaceuticals is seductive in its simplicity: be first, win big. File first, launch first, collect
Patent Expiry Timing: The Payer’s Playbook for Value-Based Contracting Offers
Every commercial contract negotiation in pharmaceuticals has a clock running in the background. That clock is the patent expiry date,
Patent Expiry Timing: The Payer’s Playbook for Value-Based Contracting Offers Read Post »
Find the Second Entrant Sweet Spot: A DrugPatentWatch Playbook for Generic and Biosimilar Strategy
The first generic filer gets the headlines. The second entrant often gets the margin. In the United States pharmaceutical market,
Drug Patents Are Breaking: How Personalized Medicine Is Exposing the Cracks
The pharmaceutical patent system was designed for a different drug. A small molecule, synthesized in a lab, dosed the same
Drug Patents Are Breaking: How Personalized Medicine Is Exposing the Cracks Read Post »
Ditch the Market Researcher: Why a Patent Analyst Suite Is the Pharma Competitive Intelligence Tool You Actually Need
Quick Summary: Traditional pharmaceutical market research tells you what happened yesterday. A patent analyst suite tells you what will happen
Reverse Engineer a Competitor’s Drug Pipeline Using Patent Filings
A competitor’s pipeline is not a secret. It is a public record, filed in tranches at the USPTO, EPO, and
Reverse Engineer a Competitor’s Drug Pipeline Using Patent Filings Read Post »
